Litcius/Paper detail

Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial

Kristian Reich, Henrique D. Teixeira, Marjolein de Bruin‐Weller, Thomas Bieber, Weily Soong, Kenji Kabashima, Thomas Werfel, Jiewei Zeng, Xiaohong Huang, Xiaofei Hu, Barbara A. Hendrickson, Barry Ladizinski, Alvina D. Chu, Jonathan I. Silverberg

2021The Lancet390 citationsDOI

Topics & Concepts

Eczema Area and Severity IndexMedicineAtopic dermatitisPlaceboDermatology Life Quality IndexJanus kinase inhibitorInternal medicineRandomized controlled trialClinical endpointAdverse effectClinical trialDermatologyJanus kinaseDiseaseCytokineAlternative medicinePathologyDermatology and Skin DiseasesAllergic Rhinitis and SensitizationPsoriasis: Treatment and Pathogenesis
Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial | Litcius